Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSTL NASDAQ:CTMX NASDAQ:ELTX NASDAQ:GYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSTLCastle Biosciences$18.91-0.7%$24.93$14.59▼$44.28$571.14M1.11395,109 shs80,326 shsCTMXCytomX Therapeutics$3.84-0.6%$4.59$1.72▼$8.21$652.68M2.185.69 million shs319,703 shsELTXElicio Therapeutics$10.82-6.8%$11.38$5.15▼$14.93$202.33M1.12130,759 shs71,678 shsGYREGyre Therapeutics$7.26+2.4%$7.53$6.57▼$11.78$704.15M2.0389,069 shs10,233 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSTLCastle Biosciences-3.98%-23.26%-17.68%-41.18%+13.40%CTMXCytomX Therapeutics-3.02%-7.66%-12.07%-30.20%+315.77%ELTXElicio Therapeutics+17.15%+8.00%+14.38%+22.08%+111.48%GYREGyre Therapeutics-5.09%-9.10%-4.06%-11.04%-25.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSTLCastle Biosciences$18.91-0.7%$24.93$14.59▼$44.28$571.14M1.11395,109 shs80,326 shsCTMXCytomX Therapeutics$3.84-0.6%$4.59$1.72▼$8.21$652.68M2.185.69 million shs319,703 shsELTXElicio Therapeutics$10.82-6.8%$11.38$5.15▼$14.93$202.33M1.12130,759 shs71,678 shsGYREGyre Therapeutics$7.26+2.4%$7.53$6.57▼$11.78$704.15M2.0389,069 shs10,233 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSTLCastle Biosciences-3.98%-23.26%-17.68%-41.18%+13.40%CTMXCytomX Therapeutics-3.02%-7.66%-12.07%-30.20%+315.77%ELTXElicio Therapeutics+17.15%+8.00%+14.38%+22.08%+111.48%GYREGyre Therapeutics-5.09%-9.10%-4.06%-11.04%-25.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSTLCastle Biosciences 2.90Moderate Buy$46.00143.21% UpsideCTMXCytomX Therapeutics 2.80Moderate Buy$12.78233.19% UpsideELTXElicio Therapeutics 2.75Moderate Buy$18.0066.36% UpsideGYREGyre Therapeutics 2.00Hold$17.00134.16% UpsideCurrent Analyst Ratings BreakdownLatest ELTX, GYRE, CSTL, and CTMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026CTMXCytomX Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $11.005/7/2026CSTLCastle Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/7/2026CSTLCastle Biosciences Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$44.00 ➝ $43.004/27/2026CSTLCastle Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/24/2026ELTXElicio Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CSTLCastle Biosciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.004/15/2026ELTXElicio Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.003/23/2026CTMXCytomX Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$10.00 ➝ $12.003/19/2026CTMXCytomX Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)3/19/2026CTMXCytomX Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$10.00 ➝ $16.003/18/2026CTMXCytomX Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $16.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSTLCastle Biosciences$344.23M1.67$1.06 per share17.81$16.13 per share1.17CTMXCytomX Therapeutics$76.20M8.57N/AN/A$0.58 per share6.61ELTXElicio TherapeuticsN/AN/AN/AN/A$0.09 per shareN/AGYREGyre Therapeutics$116.59M6.04$0.22 per share33.62$1.48 per share4.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSTLCastle Biosciences-$24.16M-$0.44N/AN/AN/A-3.78%-2.77%-2.30%N/ACTMXCytomX Therapeutics-$17.37M-$0.41N/AN/AN/A-166.40%-54.37%-36.59%N/AELTXElicio Therapeutics-$39.57M-$2.62N/AN/AN/AN/A-977.66%-141.55%N/AGYREGyre Therapeutics$5.03M-$0.09N/AN/AN/A-5.44%3.14%2.68%N/ALatest ELTX, GYRE, CSTL, and CTMX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026ELTXElicio Therapeutics-$0.49-$0.65-$0.16-$0.65N/AN/A5/7/2026Q1 2026CTMXCytomX Therapeutics-$0.14-$0.10+$0.04-$0.10$4.68 million$10.26 million5/6/2026Q1 2026CSTLCastle Biosciences-$0.49-$0.49N/A-$0.49$79.23 million$84.23 million3/16/2026Q4 2025CTMXCytomX Therapeutics-$0.08-$0.22-$0.14-$0.22$7.33 million$0.66 million3/12/2026Q4 2025ELTXElicio Therapeutics-$0.47-$0.49-$0.02-$0.49N/AN/A3/12/2026Q4 2025GYREGyre Therapeutics$0.08$0.04-$0.04-$0.02$36.30 million$37.20 million2/26/2026Q4 2025CSTLCastle Biosciences-$0.23-$0.08+$0.15-$0.08$81.19 million$81.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCSTLCastle BiosciencesN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/AELTXElicio TherapeuticsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSTLCastle Biosciences0.026.756.53CTMXCytomX TherapeuticsN/A3.093.09ELTXElicio Therapeutics5.752.382.38GYREGyre TherapeuticsN/A5.605.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSTLCastle Biosciences92.60%CTMXCytomX Therapeutics67.77%ELTXElicio Therapeutics35.03%GYREGyre Therapeutics23.99%Insider OwnershipCompanyInsider OwnershipCSTLCastle Biosciences6.10%CTMXCytomX Therapeutics6.60%ELTXElicio Therapeutics28.65%GYREGyre Therapeutics10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSTLCastle Biosciences54030.33 million28.48 millionOptionableCTMXCytomX Therapeutics170170.19 million158.96 millionOptionableELTXElicio TherapeuticsN/A18.70 million13.35 millionNot OptionableGYREGyre Therapeutics4096.99 million87.30 millionNo DataELTX, GYRE, CSTL, and CTMX HeadlinesRecent News About These CompaniesQ2 EPS Forecast for Gyre Therapeutics Reduced by AnalystMay 11 at 1:06 AM | marketbeat.comYing Luo Sells 10,136 Shares of Gyre Therapeutics (NASDAQ:GYRE) StockMay 7, 2026 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Down 11.4% on Disappointing EarningsMay 7, 2026 | marketbeat.comGyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue EstimatesMay 7, 2026 | zacks.comGyre Therapeutics Reports First Quarter 2026 Results and Provides Business UpdateMay 7, 2026 | globenewswire.comGyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical CompanyMay 4, 2026 | globenewswire.comGyre Therapeutics (GYRE) Expected to Announce Earnings on ThursdayApril 30, 2026 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Trading Up 2% - Should You Buy?April 14, 2026 | marketbeat.comGyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis TreatmentMarch 17, 2026 | markets.businessinsider.comGyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis TreatmentMarch 17, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX) and Gyre Therapeutics (GYRE)March 15, 2026 | theglobeandmail.comGyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss EstimatesMarch 12, 2026 | zacks.comGyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 12, 2026 | globenewswire.comGyre Therapeutics to acquire Cullgen in $300M all-stock transactionMarch 4, 2026 | finance.yahoo.comGyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and PipelineMarch 2, 2026 | globenewswire.comHigh Growth Tech Stocks in US for February 2026February 11, 2026 | uk.finance.yahoo.comGyre Therapeutics Advances Hydronidone Toward China ApprovalJanuary 26, 2026 | theglobeandmail.comHigh Growth Tech Stocks To Watch In The US Market January 2026January 14, 2026 | finance.yahoo.comWhy Gyre Therapeutics, Inc.’s (GYRE) Stock Is Up 7.17%January 8, 2026 | aaii.comAGyre Therapeutics announces alignment with China’s CDE on hydronidoneJanuary 5, 2026 | msn.comGyre Shares Up on Deal With Regulators for Hydronidone Conditional ApprovalJanuary 5, 2026 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELTX, GYRE, CSTL, and CTMX Company DescriptionsCastle Biosciences NASDAQ:CSTL$18.91 -0.13 (-0.66%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.CytomX Therapeutics NASDAQ:CTMX$3.84 -0.03 (-0.65%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Elicio Therapeutics NASDAQ:ELTX$10.82 -0.79 (-6.80%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.Gyre Therapeutics NASDAQ:GYRE$7.26 +0.17 (+2.40%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
